Were there any SLXN share sales or disposals reported in this Form 4?

No sales or disposals were reported. The filing only shows grant or award acquisitions of ordinary shares and stock options for Guangzhou Sino-Israel Biotech Fund, plus one line of existing option holdings that is included purely for informational purposes with no transaction effected.

Silexion director fund granted shares, options

Lushi Avner reported acquisition or exercise transactions in this Form 4 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Lushi Avner reported acquisition or exercise transactions in this Form 4 filing.

Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund, an entity associated with director Lushi Avner, received equity awards for director services. The fund was granted 9,091 ordinary shares via fully vested RSUs and 10,685 stock options. These options vest in full on the one-year anniversary of board approval and expire ten years after that approval date. An additional 1,872 stock options are reported as existing holdings with no new transaction.

Insider Trade Summary

Grant/Award: 19,776 shares

Grant/Award 3 txns

Insider Lushi Avner

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy ordinary shares)	10,685	$0.00	$0.00
Grant/Award	Ordinary Shares	9,091	$0.00	$0.00
holding	Stock Option (right to buy ordinary shares)	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 12,557 contracts for 1,872 underlying shares (Indirect, By Guangzhou Sino-Israel Biotech Fund); Ordinary Shares — 25,399 shares (Indirect, By Guangzhou Sino-Israel Biotech Fund)

Footnotes (5)

F1. The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares|), in respect of director services provided by the Reporting Person to the Issuer. The grant was approved by the Issuer's board of directors.
F2. The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.
F3. The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by the Reporting Person to the Issuer, which grant was approved by the Issuer's board of directors.
F4. The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
F5. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Silexion Therapeutics (SLXN) report for Lushi Avner?

Silexion reported equity awards to Guangzhou Sino-Israel Biotech Fund, an entity associated with director Lushi Avner. The fund received 9,091 ordinary shares through vested RSUs and 10,685 stock options, all granted as compensation for director services approved by the board.

Who actually holds the SLXN securities reported in this Form 4 filing?

The securities are held by Guangzhou Sino-Israel Biotech Fund (GIBF). Lushi Avner is a Managing Partner and CEO of GIBF and shares voting and investment authority, while disclaiming beneficial ownership except for any indirect pecuniary interest described in the footnotes.

What kind of equity awards did Guangzhou Sino-Israel Biotech Fund receive from Silexion (SLXN)?

Guangzhou Sino-Israel Biotech Fund received 9,091 ordinary shares via fully vested restricted share units and 10,685 stock options to buy ordinary shares. Both grants were made by Silexion for director services and were approved by the company’s board of directors.

How do the new SLXN stock options for Guangzhou Sino-Israel Biotech Fund vest and expire?

The options granted to Guangzhou Sino-Israel Biotech Fund vest completely on the one-year anniversary of their board approval date. They then remain exercisable until their expiration on the ten-year anniversary of that same board approval date, according to the filing footnotes.

What does the Form 4 say about existing SLXN option holdings for Guangzhou Sino-Israel Biotech Fund?

The Form 4 lists a line of 1,872 stock options held indirectly by Guangzhou Sino-Israel Biotech Fund. Footnotes explain there were no transactions in those securities, and that this position is included only to provide information about current holdings in that option series.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/23/2026 - 04:06 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lushi Avner

(Last)

(First)

(Middle)

5 NARCISSUS BOULEVARD

(Street)

RAMAT GAN

5258505

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	02/20/2026		A⁽¹⁾		9,091	A	$0	25,399	I	By Guangzhou Sino-Israel Biotech Fund⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy ordinary shares)	$1.65	02/20/2026		A⁽³⁾		10,685		02/12/2027⁽⁴⁾	02/12/2036⁽⁴⁾	Ordinary Shares	10,685	$0	10,685	I	By Guangzhou Sino-Israel Biotech Fund⁽²⁾
Stock Option (right to buy ordinary shares)⁽⁵⁾	$18.9							02/09/2026	02/09/2035	Ordinary Shares	1,872		1,872	I	By Guangzhou Sino-Israel Biotech Fund⁽²⁾

Explanation of Responses:

1. The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares|), in respect of director services provided by the Reporting Person to the Issuer. The grant was approved by the Issuer's board of directors.

2. The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.

3. The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by the Reporting Person to the Issuer, which grant was approved by the Issuer's board of directors.

4. The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.

5. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

	/s/ Mirit Horenshtein Hadar, Attorney-in-fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR